Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC108 + Furmonertinib in EGFR-mutated/MET+ NSCLC
NCT06962865Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RC108 in non-small cell lung cancer (NSCLC), sponsored by RemeGen. Started Jun 2025; status: recruiting.
02
Drugs
RC108
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06962865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06962865.